Literature DB >> 8733499

Evaluation of nebulised acetylcysteine and normal saline in the treatment of sputum retention following thoracotomy.

A M Gallon1.   

Abstract

BACKGROUND: The use of acetylcysteine as a mucolytic agent is controversial. In 1962 it was claimed to be "the most effective agent ... for the liquefaction of ... secretions" but was subsequently taken off the market as a respirator solution. Normal saline, on the other hand, is becoming increasingly popular. A study was undertaken to determine which solution is more effective at clearing retained secretions following thoracotomy.
METHODS: The study included 10 patients and was of single blind, two-way crossover design. Measurements taken before and after each treatment included sputum viscosity, difficulty of expectoration, weight of sputum expectorated, and oxygen saturation.
RESULTS: Following nebulisation of acetylcysteine, sputum viscosity was reduced, difficulty of expectoration was reduced, the weight of sputum expectorated was increased, and oxygen saturation was increased. There were no changes after nebulisation of normal saline.
CONCLUSIONS: This study shows that, following thoracotomy, nebulised acetylcysteine reduces sputum viscosity, making expectoration easier and improving oxygenation. Nebulised normal saline has no effect.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8733499      PMCID: PMC1090682          DOI: 10.1136/thx.51.4.429

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  22 in total

1.  THE IN VITRO REDUCTION IN VISCOSITY OF HUMAN TRACHEOBRONCHIAL SECRETIONS BY ACETYLCYSTEINE.

Authors:  A L SHEFFNER; E M MEDLER; L W JACOBS; H P SARETT
Journal:  Am Rev Respir Dis       Date:  1964-11

2.  Clinical evaluaton of a new mucolytic agent, acetyl-cysteine.

Authors:  W R WEBB
Journal:  J Thorac Cardiovasc Surg       Date:  1962-09       Impact factor: 5.209

3.  The effect of N-acetylcysteine on the viscosity of tracheobronchial secretions in cystic fibrosis of the pancreas.

Authors:  H W REAS
Journal:  J Pediatr       Date:  1963-01       Impact factor: 4.406

4.  Respiratory maneuvers to prevent postoperative pulmonary complications. A critical review.

Authors:  R H Bartlett; A B Gazzaniga; T R Geraghty
Journal:  JAMA       Date:  1973-05-14       Impact factor: 56.272

5.  Facemask or mouthpiece for delivery of nebulized bronchodilator aerosols?

Authors:  R D Steventon; R S Wilson
Journal:  Br J Dis Chest       Date:  1981-01

6.  Use of nebulised saline and nebulised terbutaline as an adjunct to chest physiotherapy.

Authors:  P P Sutton; H G Gemmell; N Innes; J Davidson; F W Smith; J S Legge; J A Friend
Journal:  Thorax       Date:  1988-01       Impact factor: 9.139

7.  Prevention of postoperative pulmonary atelectasis: review of 215 cases and evaluation of acetycysteine.

Authors:  P A Thomas; R E Lynch; E H Merrigan
Journal:  Am Surg       Date:  1966-05       Impact factor: 0.688

8.  No influence of acetylcysteine on gas exchange and spirometry in chronic asthma.

Authors:  G Bylin; G Hedenstierna; L Lagerstrand; P D Wagner
Journal:  Eur J Respir Dis       Date:  1987-08

9.  Oral acetylcysteine reduces exacerbation rate in chronic bronchitis: report of a trial organized by the Swedish Society for Pulmonary Diseases.

Authors:  G Boman; U Bäcker; S Larsson; B Melander; L Wåhlander
Journal:  Eur J Respir Dis       Date:  1983-08

10.  Systemic administration of N-acetylcysteine has no effect on postoperative lung function following elective upper laparotomy in lung healthy patients.

Authors:  S Jepsen; A Klaerke; P H Nielsen; S T Nielsen; O Simonsen
Journal:  Acta Anaesthesiol Scand       Date:  1989-04       Impact factor: 2.105

View more
  8 in total

1.  Precision medicine and aerosolization in mechanically ventilated adults.

Authors:  Jordi Rello; Christian Domingo
Journal:  J Thorac Dis       Date:  2018-09       Impact factor: 2.895

Review 2.  Polymeric nanoparticles in development for treatment of pulmonary infectious diseases.

Authors:  Young H Lim; Kristin M Tiemann; David A Hunstad; Mahmoud Elsabahy; Karen L Wooley
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2016-03-25

3.  Rapid transport of muco-inert nanoparticles in cystic fibrosis sputum treated with N-acetyl cysteine.

Authors:  Jung Soo Suk; Samuel K Lai; Nicholas J Boylan; Michelle R Dawson; Michael P Boyle; Justin Hanes
Journal:  Nanomedicine (Lond)       Date:  2011-02       Impact factor: 5.307

4.  Use of nebulised N-acetylcysteine as a life-saving mucolytic in intensive care: A case report.

Authors:  Elizabeth A Brodier; Meera Raithatha; Santhana Kannan; Niroshini Karunasekara
Journal:  J Intensive Care Soc       Date:  2019-09-19

5.  Pharmacological and clinical overview of cloperastine in treatment of cough.

Authors:  Maria Antonietta Catania; Salvatore Cuzzocrea
Journal:  Ther Clin Risk Manag       Date:  2011-03-07       Impact factor: 2.423

6.  Evaluation of the Effect of Nebulized N-Acetylcysteine on Respiratory Secretions in Mechanically Ventilated Patients: Randomized Clinical Trial.

Authors:  Seyed Masoom Masoompour; Amir Anushiravani; Amir Tafaroj Norouz
Journal:  Iran J Med Sci       Date:  2015-07

7.  Mucolytic Effectiveness of Tyloxapol in Chronic Obstructive Pulmonary Disease - A Double-Blind, Randomized Controlled Trial.

Authors:  Martin Koppitz; Charlotte Eschenburg; Emilia Salzmann; Martin Rosewich; Ralf Schubert; Stefan Zielen
Journal:  PLoS One       Date:  2016-06-16       Impact factor: 3.240

8.  Preventive nebulization of mucolytic agents and bronchodilating drugs in invasively ventilated intensive care unit patients (NEBULAE): study protocol for a randomized controlled trial.

Authors:  Sophia M van der Hoeven; Jan M Binnekade; Corianne A J M de Borgie; Frank H Bosch; Henrik Endeman; Janneke Horn; Nicole P Juffermans; Nardo J M van der Meer; Maruschka P Merkus; Hazra S Moeniralam; Bart van Silfhout; Mathilde Slabbekoorn; Willemke Stilma; Jan Willem Wijnhoven; Marcus J Schultz; Frederique Paulus
Journal:  Trials       Date:  2015-09-02       Impact factor: 2.279

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.